{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Moxifloxacin-Matching+Placebo&page=2", "query": { "intervention": "Moxifloxacin-Matching Placebo", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 77, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Moxifloxacin-Matching+Placebo&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Moxifloxacin-Matching+Placebo&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T12:57:11.091Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02155205", "title": "A Thorough QT Study of Telotristat Etiprate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "QT Interval" ], "interventions": [ { "name": "Telotristat etiprate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lexicon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2014-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-09-08", "last_synced_at": "2026-10-18T12:57:11.091Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02155205" }, { "nct_id": "NCT04560816", "title": "A Study of the Cardiac Effects of ALXN1840 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ALXN1840", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 57, "start_date": "2020-07-24", "completion_date": "2021-03-24", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-10-18T12:57:11.091Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04560816" }, { "nct_id": "NCT06846866", "title": "A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "BMS-986419", "type": "DRUG" }, { "name": "BMS-986419 Matching Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Moxifloxacin Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 74, "start_date": "2025-02-27", "completion_date": "2025-10-21", "has_results": false, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-10-18T12:57:11.091Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06846866" }, { "nct_id": "NCT02213029", "title": "A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Embryo Transfer" ], "interventions": [ { "name": "Epelsiban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Oxytocin", "type": "DRUG" }, { "name": "Ortho-Cylcen (21)® tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "FEMALE", "summary": "18 Years to 35 Years · Female only" }, "enrollment_count": 33, "start_date": "2014-08-28", "completion_date": "2016-02-07", "has_results": false, "last_update_posted_date": "2017-05-08", "last_synced_at": "2026-10-18T12:57:11.091Z", "location_count": 2, "location_summary": "Glendale, California • Baltimore, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213029" }, { "nct_id": "NCT04019652", "title": "The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypertension", "Mineralocorticoid Receptor Antagonist" ], "interventions": [ { "name": "CS-3150", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Placebo matching moxifloxacin tablet", "type": "DRUG" }, { "name": "Placebo matching CS-3150", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 55, "start_date": "2015-11-19", "completion_date": "2015-12-23", "has_results": false, "last_update_posted_date": "2019-07-15", "last_synced_at": "2026-10-18T12:57:11.091Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04019652" }, { "nct_id": "NCT01787357", "title": "A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Canagliflozin (JNJ-28431754)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 60, "start_date": "2008-06", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2016-06-29", "last_synced_at": "2026-10-18T12:57:11.091Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01787357" }, { "nct_id": "NCT04818229", "title": "A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autoimmune Diseases" ], "interventions": [ { "name": "CBP-307", "type": "DRUG" }, { "name": "Placebo-matched CBP-307", "type": "DRUG" }, { "name": "Moxifloxacin (Avelox)", "type": "DRUG" }, { "name": "Placebo-matched Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Connect Biopharma Australia Pty Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 112, "start_date": "2021-06-01", "completion_date": "2022-03-30", "has_results": true, "last_update_posted_date": "2024-11-04", "last_synced_at": "2026-10-18T12:57:11.091Z", "location_count": 1, "location_summary": "Hialeah, Florida", "locations": [ { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04818229" }, { "nct_id": "NCT02479308", "title": "A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "ALKS 5461", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alkermes, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 129, "start_date": "2015-06", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2015-11-23", "last_synced_at": "2026-10-18T12:57:11.091Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02479308" }, { "nct_id": "NCT07378579", "title": "An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "ESK-001", "type": "DRUG" }, { "name": "Moxifloxacin (400 mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alumis Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 52, "start_date": "2024-06-21", "completion_date": "2024-08-31", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-10-18T12:57:11.091Z", "location_count": 1, "location_summary": "Daytona Beach, Florida", "locations": [ { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07378579" }, { "nct_id": "NCT02152332", "title": "A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "JNJ-54861911-Therapeutic Dose", "type": "DRUG" }, { "name": "JNJ-54861911 - Supratherapeutic Dose", "type": "DRUG" }, { "name": "JNJ-54861911-Matched Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Moxifloxacin Matched Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 64, "start_date": "2014-07", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2014-11-24", "last_synced_at": "2026-10-18T12:57:11.091Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02152332" } ] }